Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/8541578
Conclusion of this study
All patients were treated with TUDCA (10-13 mg/day) for three months and the determination of PCNA (Proliferating Cell Nuclear Antigen) expression was used to assess the proliferative activity of hepatocytes at the beginning and at the end of treatment. TUDCA reduced both ALT and Knodell's score in the 5 patients in whom a significant increase of PCNA-LI (p < 0.05) was observed after treatment. TUDCA administration seems to stimulate hepatocyte proliferation in man.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
Digestive System |